Drug Price Trends for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM

Average Pharmacy Cost for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB	00378-5440-93	114.85972	EACH	2026-03-18
EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB	00378-5440-93	114.85972	EACH	2026-02-18

Market Analysis and Price Projections for Emtricitabine-Rilpivirine-Tenofovir Disoproxil Fumarate

Last updated: February 21, 2026

What is the current market landscape for the drug?

Emtricitabine-Rilpivirine-Tenofovir Disoproxil Fumarate (brand names such as Odefsey) targets HIV-1 infections. Approved by the FDA in 2016, it is a single-tablet regimen combining nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI). The drug's primary advantage is simplified dosing, which improves adherence.

The global HIV therapy market was valued at approximately USD 29 billion in 2021, with antiretroviral therapy (ART) accounting for a significant share. The segment for integrase inhibitors and NNRTIs is expanding, driven by new formulations and patent expirations of existing drugs.

The current market for emtricitabine-based regimens is highly competitive. Gilead Sciences, the patent holder for the drug, holds a pivotal share in the HIV treatment market. Patent expiration expected in 2027 offers potential for generic entry, possibly impacting market share and pricing.

How does the drug compare with alternative therapies?

Therapy	Dosage Form	Efficacy	Cost (Approx.)	Patent Status
Emtricitabine-Rilpivirine-Tenofovir	Single tablet daily	High	USD 30,000/year	Patent until 2027
Dolutegravir-based regimens	Single tablet daily	High	USD 25,000/year	Patent until 2029
Bictegravir-based regimens	Single tablet daily	High	USD 28,000/year	Patent until 2028

Emtricitabine-Rilpivirine-Tenofovir offers comparable efficacy to newer regimens but faces competition from drugs with longer patent protection and lower costs post-patent expiration.

What are the key drivers influencing market growth?

• Adherence and Simplification: Single-tablet regimens improve patient compliance, making the market receptive to fixed-dose combinations.
• Patent Lifecycle: With patents expiring in the late 2020s, biosimilar and generic versions could dominate, reducing prices.
• Regulatory Developments: WHO guidelines favor integrase inhibitor-based regimens but still endorse NNRTI-based fixed-dose combinations.
• Global Access Initiatives: Increased access in low-income countries, where prices are lower, expands the market.

What are the price projections based on current trends?

Initial pricing for the drug remains around USD 30,000 per year for brand-name formulations in high-income markets. Post-patent expiration (expected 2027), generic versions could reduce the price to USD 10,000 or lower annually.

Year	Estimated Price for Brand	Estimated Price for Generic	Key Factors Influencing Price
2023	USD 30,000	USD 30,000	Patent protection, market demand
2024	USD 30,000	USD 29,000	Market competition intensifies
2025	USD 30,000	USD 20,000	Near patent expiry, biosimilar development
2026	USD 30,000	USD 15,000	Launch of generics approaching
2027	USD 30,000	USD 10,000	Patent expires, entry of generics

Projected decline in prices accelerated by biosimilar competition and health authority negotiations.

How will the patent landscape influence future pricing?

• Patent expiry in 2027 opens the market for biosimilars, prompting significant price reductions.
• Patent extensions or litigation could delay generic entry, maintaining higher prices longer.
• Patent authorities evaluate challenges based on incremental innovations, influencing market entry timing.

What are the regulatory and policy implications?

• Governments and organizations like Gilead prioritize access in low-income regions, potentially affecting pricing strategies.
• Price controls and negotiated discounts are common in Europe and Asia, influencing revenue streams.
• The FDA's pathways for biosimilar approval could facilitate timely market entry for generics.

Summary of market opportunity:

• Pre-patent expiration: high-margin sales in wealthier markets.
• Post-patent expiration: surge in volume due to lower-cost generics.
• Competitive innovations may shift preference towards integrase inhibitors, risking market share.

---

Key Takeaways

• The drug’s market is mature, with steady demand due to efficacy and adherence advantages.
• Patent expiry in 2027 will likely reduce prices significantly.
• Generics could capture a majority of the market, decreasing revenue but expanding access.
• Competitive regimens, especially integrase-based, threaten market share.
• Strategic positioning before patent expiration could mitigate revenue declines.

---

FAQs

1. When is the patent expiry for emtricitabine-rilpivirine-tenofovir disoproxil fumarate?
Expected in 2027, enabling generic competition.

2. How much could prices decline post-patent expiry?
Potential reduction to USD 10,000 or lower annually per treatment course.

3. Which companies could enter the market with generics?
Multiple manufacturers, including Teva, Mylan, and Cipla, are capable of producing biosimilars once patents expire.

4. How does the drug’s efficacy compare with newer regimens?
Efficacy is comparable; newer drugs like dolutegravir-based therapies often have longer patent protections and potentially fewer side effects.

5. What strategies can maximize market share pre-2027?
Robust marketing, pricing strategies, and forming access partnerships can sustain high margins until patent expiration.

---

References

1. Gilead Sciences. (2021). Annual Report.
2. WHO. (2022). HIV/AIDS Treatment Guidelines.
3. U.S. Food and Drug Administration. (2016). Approval Announcement for Odefsey.
4. IMS Health. (2022). Global HIV Market Report.
5. PatentScope. (2023). Patent status and filings for HIV drugs.